Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Incyte Corp (INCY)
Price$126.75Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B | $2.67B | $2.16B | $1.88B | $1.54B | $1.11B | $753.8M | $511.5M | $354.9M | $297.1M | $94.5M | $169.9M | $9.3M |
| Gross profit | $4.77B | $3.93B | $3.44B | $3.19B | $2.84B | $2.54B | $2.04B | $1.79B | $1.46B | $1.05B | $726.8M | $508.5M | $354.3M | $296.9M | — | — | — |
| Gross margin | 92.76% | 92.64% | 93.10% | 93.90% | 94.94% | 95.08% | 94.71% | 95.00% | 94.83% | 94.74% | 96.42% | 99.41% | 99.82% | 99.95% | — | — | — |
| Research & development | $2.05B | $2.61B | $1.63B | $1.59B | $1.46B | $2.22B | $1.15B | $1.20B | $1.33B | $581.9M | $479.5M | $347.5M | $260.4M | $210.4M | $178.7M | $123.9M | $119.4M |
| Operating expenses | $3.63B | $4.18B | $3.08B | $2.82B | $2.40B | $2.93B | $1.76B | $1.75B | $1.78B | $960.7M | $703.1M | $516.3M | $371.0M | $295.9M | $237.6M | $155.8M | $149.0M |
| Operating income | $1.51B | $61.4M | $620.5M | $579.4M | $585.8M | −$263.7M | $402.0M | $129.2M | −$243.4M | $145.0M | $50.7M | −$4.8M | −$16.1M | $1.1M | −$143.2M | $14.0M | −$139.8M |
| Operating margin | 29.46% | 1.45% | 16.79% | 17.07% | 19.62% | −9.89% | 18.62% | 6.87% | −15.84% | 13.11% | 6.72% | −0.94% | −4.54% | 0.39% | −151.59% | 8.27% | −1,508.56% |
| EBITDA | $1.61B | $150.6M | $703.2M | $647.3M | $643.6M | −$211.9M | $456.5M | $184.2M | −$191.2M | $203.4M | $95.5M | $36.6M | $13.1M | $31.1M | −$116.2M | $38.5M | −$123.1M |
| EBITDA margin | 31.28% | 3.55% | 19.03% | 19.07% | 21.55% | −7.94% | 21.15% | 9.79% | −12.45% | 18.40% | 12.67% | 7.16% | 3.69% | 10.48% | −123.01% | 22.68% | −1,328.42% |
| Net income | $1.29B | $32.6M | $597.6M | $340.7M | $948.6M | −$295.7M | $446.9M | $109.5M | −$313.1M | $104.2M | — | — | — | — | — | — | — |
| Net profit margin | 25.03% | 0.77% | 16.17% | 10.04% | 31.76% | −11.09% | 20.70% | 5.82% | −20.38% | 9.43% | — | — | — | — | — | — | — |
| Basic EPSper basic share | $6.59 | $0.16 | $2.67 | $1.53 | $4.30 | -$1.36 | $2.08 | $0.52 | -$1.53 | $0.55 | $0.04 | -$0.29 | -$0.56 | -$0.34 | -$1.49 | -$0.26 | -$2.06 |
| Diluted EPSper diluted share | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | -$1.36 | $2.05 | $0.51 | -$1.53 | $0.54 | $0.03 | -$0.29 | -$0.56 | -$0.34 | -$1.49 | -$0.26 | -$2.06 |
Owners
Reported shareholders
15.31%of listed shares
BAKER BROS. ADVISORS LP30.76M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BAKER BROS. ADVISORS LP | 15.31%30.76M shares |
BlackRock, Inc. | 8.97%18.03M shares |
Dodge & Cox | 5.95%11.96M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 5.49%11.02M shares |
STATE STREET CORP | 4.84%9.72M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.88%7.79M shares |
AQR CAPITAL MANAGEMENT LLC | 2.65%5.32M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.36%4.75M shares |
LSV ASSET MANAGEMENT | 2.05%4.12M shares |
Invesco Ltd. | 2.03%4.08M shares |
WELLINGTON MANAGEMENT GROUP LLP | 1.78%3.58M shares |
RENAISSANCE TECHNOLOGIES LLC | 1.75%3.51M shares |
MORGAN STANLEY | 1.47%2.95M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.37%2.74M shares |
Robeco Institutional Asset Management B.V. | 1.21%2.44M shares |
GOLDMAN SACHS GROUP INC | 1.15%2.31M shares |
DIMENSIONAL FUND ADVISORS LP | 1.13%2.28M shares |
TWO SIGMA INVESTMENTS, LP | 1.00%2M shares |
NORTHERN TRUST CORP | 0.88%1.76M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.84%1.69M shares |
Percentages use 200.98M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 4, 2026Form 4 · 10b5-1 | Tray ThomasPrincipal Accounting Officer | SellCommon Stock | 2.6K | $100.00 | $263.9K | 21.1K |
| May 26, 2026Form 4 · 10b5-1 | Tray ThomasPrincipal Accounting Officer | SellCommon Stock | 2.1K | $97.35 | $199.7K | 21.1K |
| May 19, 2026Form 4 · 10b5-1 | Clancy Paul JDirector | SellCommon Stock | 15.0K | $94.93 | $1.42M | 23.7K |
| Apr 17, 2026Form 4 · 10b5-1 | CAGNONI PABLO JPresident, Global Head of R&D | SellCommon Stock | 18.7K | $96.50 | $1.80M | 262.7K |
| Mar 17, 2026Form 4 · 10b5-1 | CAGNONI PABLO JPresident, R&D | SellCommon Stock | 18.7K | $94.24 | $1.76M | 234.8K |
Community posts
Incyte expands Opzelura partnership to Australia
Incyte ($INCY) expanded its partnership with Specialised Therapeutics to include Opzelura in Australia. The arrangement assigns local regulatory submissions, medical affairs, marketing and distribution responsibilities to the partner, while ...
